DKSH has signed an agreement to acquire Biomedic, a Hanoi‑based distributor of diagnostic and screening solutions, for undisclosed terms with the transaction expected to close in Q1 2026; the purchase is intended to bolster DKSH’s Technology business in Vietnam by adding Biomedic’s application expertise and nationwide sales, service and application specialist teams. Biomedic, founded in 2008, employs more than 80 people across three locations, generates roughly CHF 12 million in annual net sales with good profitability, and serves hospitals, testing centers and fertility clinics. The deal expands DKSH’s presence in Vietnam’s growing life‑sciences and healthcare market and could drive incremental revenue and margin upside; DKSH shares closed up 0.53% at CHF 57.30 on the Swiss exchange.
DKSH announced an agreement to acquire Biomedic, a Hanoi-based distributor of diagnostic and screening solutions, with the transaction expected to close in Q1 2026 and terms remaining undisclosed. The target was founded in 2008, employs more than 80 people across three Vietnamese locations, and generates roughly CHF 12 million in annual net sales with "good profitability," serving hospitals, testing centers and fertility-support clinics. Management frames the deal as a reinforcement of DKSH's Technology business by adding Biomedic's application expertise and nationwide sales, service and application specialist teams to deepen exposure to Vietnam's life-sciences and healthcare markets. Market response was mutedly positive, with DKSH shares closing up 0.53% at CHF 57.30; key near-term uncertainties are the undisclosed financial terms, integration execution and the magnitude of incremental revenue and margin contribution once the acquisition is consolidated.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
